TY  - JOUR
AU  - Owonikoko, Taofeek K
AU  - Niu, Huifeng
AU  - Nackaerts, Kristiaan
AU  - Csoszi, Tibor
AU  - Ostoros, Gyula
AU  - Mark, Zsuzsanna
AU  - Baik, Christina
AU  - Joy, Anil Abraham
AU  - Chouaid, Christos
AU  - Jaime, Jesus Corral
AU  - Kolek, Vitezslav
AU  - Majem, Margarita
AU  - Roubec, Jaromir
AU  - Santos, Edgardo S
AU  - Chiang, Anne C
AU  - Speranza, Giovanna
AU  - Belani, Chandra P
AU  - Chiappori, Alberto
AU  - Patel, Manish R
AU  - Czebe, Krisztina
AU  - Byers, Lauren
AU  - Bahamon, Brittany
AU  - Li, Cong
AU  - Sheldon-Waniga, Emily
AU  - Kong, Eric F
AU  - Williams, Miguel
AU  - Badola, Sunita
AU  - Shin, Hyunjin
AU  - Bedford, Lisa
AU  - Ecsedy, Jeffrey A
AU  - Bryant, Matthew
AU  - Jones, Sian
AU  - Simmons, John
AU  - Leonard, E Jane
AU  - Ullmann, Claudio Dansky
AU  - Spigel, David R
AU  - C14018 study investigators
PY  - 2019
DO  - 10.1016/j.jtho.2019.10.013
UR  - http://hdl.handle.net/10668/15444
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - We assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel (henceforth referred to as alisertib/paclitaxel) as second-line treatment for SCLC. In this double-blind study, patients with relapsed or refractory SCLC were stratified by relapse...
LA  - en
KW  - Alisertib
KW  - Aurora A kinase
KW  - Paclitaxel
KW  - Phase II
KW  - SCLC
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Azepines
KW  - Biomarkers
KW  - Disease-Free Survival
KW  - Double-Blind Method
KW  - Humans
KW  - Lung Neoplasms
KW  - Neoplasm Recurrence, Local
KW  - Paclitaxel
KW  - Pyrimidines
KW  - Retrospective Studies
KW  - Treatment Outcome
TI  - Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.
TY  - research article
VL  - 15
ER  -